CA Patent

CA2973540A1 — Treatment of autoimmune disease in a patient receiving additionally a beta-blocker

Assigned to Novartis AG · Expires 2016-09-01 · 10y expired

What this patent protects

The present invention relates to methods of treating autoimmune diseases with siponimod in patients receiving additionally a beta-blocker. In some embodiments, siponimod is for administration via an initial titration regimen, followed by a regimen wherein the beta-blocker is adde…

USPTO Abstract

The present invention relates to methods of treating autoimmune diseases with siponimod in patients receiving additionally a beta-blocker. In some embodiments, siponimod is for administration via an initial titration regimen, followed by a regimen wherein the beta-blocker is added to the patient's therapy on, at the earliest, day1of a maintenance regimen.

Drugs covered by this patent

Patent Metadata

Patent number
CA2973540A1
Jurisdiction
CA
Classification
—
Expires
2016-09-01
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.